ArticleCritical care (London, England)2023
Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry.
Article in Critical care (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04391920 (Registry of CytoSorb Therapy in COVID-19 ICU Patients), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Registry of CytoSorb Therapy in COVID-19 ICU Patients (CTC REGISTRY): Registry of Patient-level Clinical Data on CytoSorb Hemoadsorption Provided Via Integration of the CytoSorb Device Into Extracorporeal Membrane Oxygenation (ECMO), Continuous Renal Replacement Therapy (CRRT), or Hemoperfusion Extracorporeal Circuits in COVID-19 ICU Patients
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Hemoperfusion during extracorporeal membrane oxygenation: an updated systematic review and meta-analysis of 8,151 patients.Critical care (London, England) · 2026Pooled it
- Hemoadsorption in acute respiratory distress syndrome patients requiring venovenous extracorporeal membrane oxygenation: a systematic review.Respiratory research · 2024Pooled it
- Extracorporeal multi-organ support: ECMO, CRRT, and hemoperfusion for acute alcohol intoxication with renal and respiratory failure.Renal failure · 2025Article
- The international, prospective CytOSorbJournal of intensive medicine · 2025Article
- Critical risks of haemoadsorption for COVID-19 patients and directions for future evaluations: a nationwide propensity score matched cohort study.Scientific reports · 2025Observational
- Extracorporeal Membrane Oxygenation Modulates the Inflammatory Milieu and Organ Failure Trajectory in Severe COVID-19 and Sepsis.Journal of clinical medicine · 2025Article
- Efficacy of hemoadsorption in the severe course of COVID-19.Frontiers in medicine · 2025Article
- Beyond conventional care: The therapeutic potential of hemoperfusion in severe COVID-19.World journal of critical care medicine · 2024Article
- Endothelial Protection and Improved Micro- and Macrocirculation with Hemoadsorption in Critically Ill Patients.Journal of clinical medicine · 2024Review
- The COSMOS Registry of CytoSorb Hemoadsorption Therapy in Critically Ill Patients: Protocol for an International, Prospective Registry.JMIR research protocols · 2024Observational
- Use of Extracorporeal Membrane Oxygenation for Patients with Coronavirus Disease 2019 Infection.Advances in surgery · 2024Review
- Extracorporeal organ support for critically ill patients: Overcoming the past, achieving the maximum at present, and redefining the future.World journal of critical care medicine · 2024Article
- Complications during Veno-Venous Extracorporeal Membrane Oxygenation in COVID-19 and Non-COVID-19 Patients with Acute Respiratory Distress Syndrome.Journal of clinical medicine · 2024Article
- Systematic review with expert consensus on use of extracorporeal hemoadsorption in septic shock: An Indian perspective.World journal of critical care medicine · 2024Article
- A Contemporary Review of the Use of Extracorporeal CytoSorbJournal of clinical medicine · 2024Review
- Prone Positioning and Molecular Biomarkers in COVID and Non-COVID ARDS: A Narrative Review.Journal of clinical medicine · 2024Review
- Reply to Supady et al. Comment on: Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry.Critical care (London, England) · 2023Article
- Post VV-ECMO Weaning Hyperinflammation-Can Prophylactic Hemoadsorption Treatment Prevent Complications?Medicina (Kaunas, Lithuania) · 2023Article
- Blood purification in critically ill patients: not enough, but still helpful.Critical care (London, England) · 2023Article
- [Cytokine adsorption in extracorporeal membrane oxygenation].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 7 institutions in 3 countries.
Funding
Abstract
objectivesThe CytoSorb therapy in COVID-19 (CTC) registry evaluated the clinical performance and treatment parameters of extracorporeal hemoadsorption integrated with veno-venous extracorporeal membrane oxygenation (VV ECMO) in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS) and respiratory failure under US FDA Emergency Use Authorization.
designMulticenter, observational, registry (NCT04391920).
settingIntensive care units (ICUs) in five major US academic centers between April 2020 and January 2022. PATIENTS: A total of 100 critically ill adults with COVID-19-related ARDS requiring VV ECMO support, who were treated with extracorporeal hemoadsorption.
interventionsNone. MEASUREMENTS AND MAIN
resultsBaseline demographics, clinical characteristics, laboratory values and outcomes were recorded following individual ethics committee approval at each center. Detailed data on organ support utilization parameters and hemoadsorption treatments were also collected. Biomarker data were collected according to the standard practice at each participating site, and available values were compared before and after hemoadsorption. The primary outcome of mortality was evaluated using a time-to-event analysis. A total of 100 patients (63% male; age 44 ± 11 years) were included. Survival rates were 86% at 30 days and 74% at 90 days. Median time from ICU admission to the initiation of hemoadsorption was 87 h and was used to define two post hoc groups: ≤ 87 h (group-early start, G
conclusionsIn critically ill patients with severe COVID-19-related ARDS treated with the combination of VV-ECMO and hemoadsorption, 90-day survival was 74% and earlier intervention was associated with shorter need for organ support and ICU stay. These results lend support to the concept of "enhanced lung rest" with the combined use of VV-ECMO plus hemoadsorption in patients with ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.